|
|
|
|
|
13.10.25 - 17:48
|
Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates (Business Wire)
|
|
|
U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year
Commercial momentum highlighted by a doubling of U.S. system sales year-to-date
Adding to U.S. commercial team to support organic demandPARIS & BOSTON--(BUSINESS WIRE)--Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced its revenue for the third quarter of 2025, up 16% at constant exchange rates (CER).
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, stated: “I am pleased with our significantly improved performance in the third quarter, reflecting the acceleration of our commercial momentum in the U.S., where we are benefiting from very positive clinical data presented earlier this year, strong support from a large group of leading physicians and attractive reimbursement. Responding to strengthening market demand, we have elected to expand our U.S. ...
|
|
|
13.10.25 - 17:48
|
Eurofins Scientific SE: Weekly Report on Share Repurchases from 06th October to 10th October 2025 (Business Wire)
|
|
|
LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific SE (Paris:ERF):
Name of the Issuer
Identify code of the Issuer
Transaction day
Identify code of the financial instrument
Total daily volume (in number of shares)
Daily weighted average purchase price of the shares
Market (MIC Code)
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
06/10/2025
FR0014000MR3
10 000
62.2576
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
07/10/2025
FR0014000MR3
10 000
62.1582
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
08/10/2025
FR0014000MR3
10 000
62.2099
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
09/10/2025
FR0014000MR3
10 000
62.6027
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
10/10/2025
FR0014000MR3
10 000
62.7664
XPAR
TOTAL
50 000
62.3990
Transaction details
In accordance with Article 5(1)(b) of Regulation (EU) N° 596/2014 (the Market Abuse Regulation) a full breakdown of the individual trades are disclosed on Eurofins Scientific SE website: https://www.eurofins.com/investors/share-buy-back-progra...
|
|
|
|
|
|
|
|
|
|
|
|
|
10.10.25 - 21:03
|
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder (GlobeNewswire EN)
|
|
|
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY® (risperidone) as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder (BD-I) in adults. The approval is based on existing clinical data for UZEDY, coupled with Model-Informed Drug Development (MIDD) methodologies that leverage previous findings on the safety and efficacy of risperidone formulations already approved for BD-I....
|
|
|
|
|
|
|
10.10.25 - 09:54
|
Sartorius Stedim Biotech Neutral (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Sartorius Stedim auf "Neutral" mit einem Kursziel von 220 Euro belassen. Matthew Weston sieht seine Umsatzschätzung für die Mitte Oktober anstehenden Quartalszahlen der Sartorius-Tochter knapp ......
|
|
|
|
|
|
|
|
|
|
|
09.10.25 - 13:48
|
Eurofins Scientific: Director/PDMR Shareholding (Business Wire)
|
|
|
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1.
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Analytical Bioventures S.C.A (RCS B89265)
23, Va Fleuri, L-1526 Luxembourg
2.
Reason for the notification
a)
Position / status
Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin
b)
Initial notification / amendment
Initial
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Eurofins Scientific S.E.
b)
LEI
529900JEH...
|
|
|
09.10.25 - 09:01
|
Johnson & Johnson Aktie vor weiteren Kursanstieg (Aktiencheck)
|
|
|
Paris (www.aktiencheck.de) - Johnson & Johnson Aktie vor weiteren Kursanstieg
Die Johnson & Johnson-Aktie (ISIN: US4781601046, WKN: 853260, Ticker-Symbol: JNJ, NYSE-Symbol: JNJ) befindet sich nach dem Abprall an der Unterstützungszone um 142,80/143,00 USD im April in einem Aufwärtstrend, wie aus der Veröffentlichung "dailyAKTIEN" der BNP Paribas hervorgeht. [mehr]...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
